Protagenic Therapeutics files suit to rescind Phytanix Bio acquisition or seek damages

Protagenic Therapeutics, Inc.new

Filed Verified Complaint in Delaware Chancery Court on October 28, 2025.
Seeks rescission of May 15, 2025 Share Exchange Agreement acquiring Phytanix Bio.
Alternatively seeks damages and an order compelling delivery of audited financials.
Lawsuit challenges the entire transaction; no settlement or resolution disclosed.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.